Core Insights - Clarivate Plc (NYSE:CLVT) is actively pursuing AI initiatives, notably with the launch of Clarivate Nexus, an AI-powered academic assistant aimed at enhancing library content and services for students and researchers [1][2] Company Developments - Clarivate Nexus will initially be available as a browser extension, with plans for future integration into campus systems, including learning management systems and library portals, set for early access in Q3 2026 [2] - The company has entered a multi-year agreement with Iran's Ministry of Higher Education and Scientific Research, focusing on strategic guidance, data analytics, and skills development [2] Business Segments - Clarivate operates in three main segments: academic-focused AI services, intellectual property (IP) management software, and life sciences and healthcare research and development tools [3]

Recognized as the Global Leader in Merchant NAND Flash Controller Innovation th Clarivate evaluates organizations based on comprehensive metrics, including patent influence, success, globalization, and technical distinctiveness. Silicon Motion's inaugural inclusion in this list highlights not only our robust performance in accumulating patent volume but also our significant advantages in 'Grant Rate' and 'Downstream Influence.' This achievement underscores our success in transforming R&D innovations into hi ...

About Clarivate Clarivateâ"¢ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com. LONDON, Jan. 28, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the fourth qu ...

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Clarivate Nexus integrates academic content and services into the AI tools increasingly used by students and researchers, helping libraries and institutions remain central to trusted scholarship. LONDON, Jan. 22, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced Clarivate Nexus, the first academic assistant designed to reconnect students and researchers with library content and services directly in the AI tools they use. Its developmen ...

Core Insights - Kioxia Corporation has been recognized as a Clarivate Top 100 Global Innovators for 2026, marking the fifth time the company has received this award for its achievements in intellectual property [1]. Company Recognition - The award is presented to the most innovative global companies and organizations, based on Clarivate's proprietary analysis of intellectual property [1].

Core Viewpoint - Royal Philips has been recognized as a Clarivate Top 100 Global Innovator for 2026, marking the 13th consecutive year of this achievement, highlighting its leadership in healthcare innovation [2][6]. Group 1: Innovation and R&D Commitment - Philips invests over EUR 1.7 billion annually in R&D, which is approximately 9% of its sales, positioning it among the highest in the industry [3][6]. - The company focuses on AI-enabled technologies, advanced imaging, and connected platforms to enhance diagnosis precision and streamline workflows [3][6]. Group 2: Notable Innovations - Philips Verida is introduced as the world's first detector-based spectral CT, integrating AI throughout the imaging process [7]. - The company has developed helium-free MRI magnet technology, saving over six million liters of liquid helium and eliminating the need for refills in hospitals [7]. - The Philips Flash 5100 Point-of-Care Ultrasound offers advanced imaging clarity and an intuitive workflow for frontline clinical decision-making [7]. - A next-generation web-based diagnostic viewer has been created to improve how radiologists access and interpret medical images [7]. - AI-enabled personal care innovations, such as the Philips i9000 Shaver Series, provide personalized self-care experiences for consumers [7]. Group 3: Company Overview - Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people, with operations in over 100 countries [8].

Core Insights - The 2026 report of the Top 100 Global Innovators highlights a shift in innovation leadership from scale to precision, with artificial intelligence (AI) playing a crucial role in this transformation [1][2][3] Group 1: Innovation Leadership - The Top 100 Global Innovators contribute 16% of the world's strongest AI inventions, emphasizing that leadership is defined by quality and strategic intent rather than just volume [3] - Recognition as a Top 100 Global Innovator is a significant achievement, with 16 organizations being all-time recipients, indicating sustained excellence in innovation [3][6] Group 2: AI Impact - AI-related patent activity has surged, with filings doubling repeatedly since 2019, leading to over one million invention specifications published by mid-2025 [3] - Generative AI and deep learning are identified as the fastest-moving frontiers in technology, reshaping the landscape of innovation [3] Group 3: Geographic Distribution - Japan leads the global innovation landscape with 32 organizations, including five in the top 10, followed by Mainland China and South Korea with two each, and the United States with one [4] - The United States has 18 organizations in the Top 100, while Taiwan has 12, and both Germany and South Korea have eight [4] Group 4: New and Returning Innovators - Samsung Electronics retains its position as the 1 ranked global innovator, while six companies are recognized for the first time in the Top 100 [6] - Six companies have re-entered the Top 100, including Apple and Saudi Aramco, while 16 all-time recipients maintained their status [6]

Group 1: Hilton Hotels (HLT) - The Department of Homeland Security (DHS) criticized Hilton Hotels for allegedly canceling reservations for Immigration and Customs Enforcement (ICE) officers at a Minneapolis hotel, claiming it was a coordinated campaign to refuse service to DHS law enforcement [3][4] - Following the incident, shares of Hilton (HLT) fell nearly 2.5% [4] - A spokesperson for Hilton stated that the hotel involved is independently owned and operated, and the actions taken were not reflective of Hilton's values, emphasizing that the company does not tolerate discrimination [5] Group 2: Hawaiian Electric Industries (HE) - Hawaiian Electric reached a $47.75 million settlement with shareholders who accused the company of misleading them about wildfire prevention and safety protocols prior to the 2023 Maui wildfires [6][7] - Shareholders alleged that Hawaiian Electric falsely claimed it was taking appropriate actions to mitigate wildfire risks associated with its utility poles; the company denied wrongdoing but agreed to the settlement [7] - The settlement is pending approval from a U.S. District Court in San Francisco [8] Group 3: Clarivate (CLVT) - Clarivate released its 2026 Drugs to Watch report, highlighting 11 therapies expected to provide significant clinical benefits and strong commercial potential [8] - The report focuses on therapies that may transform treatment for various diseases, including metabolic, cancer, immune, rare, and neurological conditions, with potential major impacts within five years [9]